VOR BIOPHARMA INC

RA Capital’s $2 million stake in VOR BioPharma signals renewed confidence in its low‑toxicity cancer‑targeting cell therapy pipeline, potentially fast‑tracking clinical trials and FDA approvals.

RA Capital’s June 2026 option buy of Vor BioPharma’s 57,162 shares—just $0.02 above market—aligns with China’s telitacicept approvals, hinting at sustainable upside for investors seeking high‑risk biotech plays.

TCG Crossover GP II’s steady 2.84 M‑share stake in Vor BioPharma signals long‑term confidence despite insider sell‑offs, hinting at upside if trials succeed.

Explore how insider moves, institutional stability, and a Phase III Sjögren’s trial shape Vor BioPharma’s risk‑reward profile—and what it means for investors.